Kaléo

Study finds AUVI-Q® prescriptions linked to lower rates of anaphylaxis-related hospitalizations compared to other epinephrine auto-injectors.

Walgreens becomes the first retail pharmacy to offer AUVI-Q® auto-injectors at no cost for eligible patients, improving access during supply shortages.

Kaléo Medical Affairs team discusses supporting caregivers of people with food allergies, offering advice and resources for managing food allergies and anaphylaxis.

Kaléo spearheaded the Early Childhood Anaphylaxis Collaborative to improve preparedness for food allergic emergencies in early childcare settings, focusing on education, resources, and access to undesignated epinephrine.

The FDA approved Kaléo’s Naloxone Auto-Injector 10 mg for emergency treatment and temporary prophylaxis in military personnel and chemical incident responders facing high-potency opioid threats.

Marathon Asset Management acquired Kaléo to accelerate its growth in the development, manufacture, and commercialization of life-transforming medical products. The acquisition is expected to drive expansion in anaphylaxis and other serious medical conditions.

Christine Waite was appointed as vice president, marketing and analytics, to drive growth and a consumer-focused approach for Kaléo’s marketed products.

Alfred Tenuto was named Chief Commercial Officer and Mark A. Herzog as Vice President, Global Corporate Affairs, Defense and Homeland Security, leading the new Government Sector business unit focused on medical countermeasures.

Kaléo announced five new appointments at the C-suite and management levels to promote business and growth strategies.

Kaléo reintroduced AUVI-Q® to the U.S. market with revamped manufacturing and quality systems to ensure reliable and accurate epinephrine dose delivery.

Intelliject, Inc. (now Kaléo) secured $15 million in debt financing from Hercules Technology Growth Capital to accelerate the development of key pipeline products.

Patent covers aspects of the electronic voice and visual instruction technology included in the FDA approved EVZIO® (naloxone HCl injection) Auto-injector. Kaléo has been awarded over 200 patents covering drug products, auto-injector platforms, demonstration devices, compliance tracking solutions, and other novel technologies.